Equities research analysts forecast that Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) will post sales of $74.40 million for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Pacira Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $70.80 million and the highest estimate coming in at $78.06 million. Pacira Pharmaceuticals reported sales of $69.28 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.4%. The business is scheduled to issue its next earnings report on Thursday, May 3rd.
On average, analysts expect that Pacira Pharmaceuticals will report full year sales of $316.37 million for the current year, with estimates ranging from $311.40 million to $333.69 million. For the next financial year, analysts anticipate that the firm will post sales of $369.85 million per share, with estimates ranging from $343.00 million to $423.44 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Pacira Pharmaceuticals.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.46. The firm had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.09 EPS.
NASDAQ PCRX traded down $1.10 during trading hours on Tuesday, reaching $33.45. The company’s stock had a trading volume of 1,628,686 shares, compared to its average volume of 1,212,933. Pacira Pharmaceuticals has a fifty-two week low of $26.95 and a fifty-two week high of $52.47. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.96 and a quick ratio of 6.22.
Hedge funds have recently made changes to their positions in the company. First Republic Investment Management Inc. purchased a new position in shares of Pacira Pharmaceuticals during the 4th quarter worth about $201,000. Bouchey Financial Group Ltd purchased a new position in shares of Pacira Pharmaceuticals during the 4th quarter worth about $205,000. Twin Focus Capital Partners LLC purchased a new position in shares of Pacira Pharmaceuticals during the 4th quarter worth about $206,000. Redmile Group LLC purchased a new position in shares of Pacira Pharmaceuticals during the 4th quarter worth about $237,000. Finally, Fisher Asset Management LLC purchased a new position in shares of Pacira Pharmaceuticals during the 4th quarter worth about $241,000.
COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals Inc. (PCRX) Expected to Announce Quarterly Sales of $74.40 Million” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://dakotafinancialnews.com/2018/04/10/zacks-brokerages-anticipate-pacira-pharmaceuticals-inc-pcrx-will-announce-quarterly-sales-of-74-39-million.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.